Evicenter
P&T meetings

Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer
Hansa Biopharma
Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Economic information and modeling reportBudget impact model

Budget impact model discussion

1 evidence topic · 1 source

Summary

The five-year estimate remains an additional cost after dialysis offsets. Inputs include 20 eligible patients, four to five transplants annually, and a 6.5% second-dose rate. The model uses Irish prices and rebates. Its lifetime cost-effectiveness result should not be interpreted as a five-year budget saving.